These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 527004)

  • 1. [Type II hyperlipoproteinaemia treated with etiroxate (author's transl)].
    Vondra K; Válek J; Dobiásová M; Honzák R
    Cas Lek Cesk; 1979 Oct; 118(40-41):1251-5. PubMed ID: 527004
    [No Abstract]   [Full Text] [Related]  

  • 2. [Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)].
    Zadák Z; Kalinová M; Sobotka L
    Cas Lek Cesk; 1982 May; 121(19):593-5. PubMed ID: 7093991
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of colestipol on plasma lipids in patients affected by type Ii primary hyperlipoproteinaemia (author's transl)].
    Drouin P; Sauvanet JP; Lambert D; Mejean L; Debry G
    Therapie; 1980; 35(4):457-64. PubMed ID: 7466730
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)].
    Schwartzkopff W; Russ E
    MMW Munch Med Wochenschr; 1975 May; 117(19):827-30. PubMed ID: 805950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
    Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
    Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextrothyroxine induced hyperthyroidism in a patient with heterozygous familial hypercholesterolaemia.
    Hazenberg HJ; Muller CJ; Kerckhoffs HP; Erkelens DW
    Neth J Med; 1987 Oct; 31(3-4):117-21. PubMed ID: 3683682
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
    Graisely B; Cloarec M
    Sem Hop; 1980 Jun 18-25; 56(25-28):1221-5. PubMed ID: 6256875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
    Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W
    Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperlipoproteinemia type II].
    Schade RW
    Ned Tijdschr Geneeskd; 1980 Dec; 124(51):2172-81. PubMed ID: 6782494
    [No Abstract]   [Full Text] [Related]  

  • 15. [Type II familial hyperlipoproteinaemia : value of plasma exchange treatment (author's transl)].
    Jan F; Sylvestre R; Jacotot B; Arulnaden JL; Poindron JY; Beaumont JL
    Ann Med Interne (Paris); 1982; 133(2):110-3. PubMed ID: 7081867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A; Ljachnicky N
    Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tendinous hyperlipoproteinaemic xanthomatosis associated with supravalvular aortic xanthomatosis (author's transl)].
    Rouffy J; Bouthillier D; Chanu B; Bakir R; Acar J; Cabrol C; Chomette G
    Ann Med Interne (Paris); 1981; 132(5):316-8. PubMed ID: 7294592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia.
    Lowe GD; Drummond MM; Third JL; Bremner WF; Forbes CD; Prentice CR; Lawrie TD
    Thromb Haemost; 1980 Feb; 42(5):1503-7. PubMed ID: 7368154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.